SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as traders closely monitor its struggle to hold the 80k level, with bullish sentiment fueled by anticipation of upcoming U.S. employment data and the potential impact of the Clarity Act on market liquidity. While bulls look for a breakout towards 85k-90k, some market participants remain cautious, expressing uncertainty over the sustainability of recent gains and the potential for a pullback during the upcoming holiday weekend.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood shares are surging following a series of Wall Street analyst price target upgrades and a growing consensus that the firm is successfully diversifying beyond cyclical brokerage services into prediction markets and blockchain infrastructure. While some traders express skepticism regarding the sustainability of the rally, many are highlighting the firm's expanding financial ecosystem and product innovation as key long-term catalysts.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is experiencing significant volatility and consolidation as traders debate whether current price levels present a deep-value opportunity or a sign of persistent technical manipulation. Many investors maintain a bullish long-term outlook, citing strong fundamental growth and ad-tech sector tailwinds, while others express frustration over the stock's tendency to fade after daily gains.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Investors are actively debating Lululemon's outlook ahead of its upcoming earnings report, with community sentiment divided between those betting on a turnaround under new leadership and those skeptical of continued growth amid retail headwinds. Michael Burry's bullish stance remains a central talking point, with traders closely monitoring volume signals and potential upside from tariff refunds despite broader concerns about the company's valuation and market competitiveness.

Planet Labs PBC provides daily data and insights about earth. It offers a web-geo platform with satellite data available and foundational analytics to derive insights to make decisions. The company is founded by William S. Marshall and Robert H. Schingler in 2010 and is headquartered in San Francisco, CA.

Planet Labs PBC - Ordinary Shares - Class A

Planet Labs PBC

Planet Labs is facing significant selling pressure and volatility, with investors expressing frustration over a sharp decline from recent highs. Much of the conversation centers on speculation that earnings results may have been leaked or that the stock is suffering from sector-wide sentiment deterioration and ongoing institutional rotation.

Hewlett Packard Enterprise Co. is a global edge-to-cloud company, which engages in the provision of information technology, technology and enterprise products, solutions, and services. It operates through the following segments: Server, Hybrid Cloud, Intelligent Edge, Financial Services, and Corporate Investments and Other. The Server segment consists of general-purpose servers for multi-workload computing and workload-optimized servers to deliver the performance and value for demanding applications, and integrated systems comprised of software and hardware designed to address high-performance computing and supercomputing, artificial intelligence, data analytics, and transaction processing workloads for government and commercial customers globally. The Hybrid Cloud segment is involved in a variety of cloud-native and hybrid solutions across storage, private cloud, and the infrastructure software-as-a-service space. The Intelligent Edge segment offers wired and wireless local area networks, campus, branch, and data center switching, software-defined wide-area-networks, private and public cellular network software, network security, and associated services that enable secure connectivity for businesses of any size. The Financial Services segment provides investment solutions, such as leasing, financing, IT consumption, utility programs, and asset management services for customers that facilitate technology deployment models and the acquisition of complete IT solutions, including hardware, software, and services from Hewlett Packard Enterprise and others. The Corporate Investments and Other segment includes the Advisory and Professional Services business, which primarily offers consultative-led services, HPE and partner technology expertise and advice, implementation services, as well as complex solution engagement capabilities, the Communications and Media Solutions business, which primarily offers software and related services to the telecommunications industry, and Hewlett Packard Labs, which is responsible for research and development. The company was founded by William R. Hewlett and David Packard on July 2, 1939 and is headquartered in Spring, TX.

Hewlett Packard Enterprise Co

Hewlett Packard Enterprise shares are trending following a strong quarterly earnings report that featured revenue and earnings beats alongside raised full-year guidance, though the stock experienced initial volatility as investors weighed management's comments on margin pressure and supply chain constraints. Despite the after-hours price dip, community sentiment remains largely bullish, with many traders viewing the pullback as a buying opportunity given the company's role in the AI infrastructure buildout and analyst price target increases.

Snowflake, Inc. engages in the provision of cloud data warehousing software. The firm offers Data Cloud, an ecosystem where Snowflake customers, partners, data providers, and data consumers can break down data silos and derive value from data. Its platform supports a range of use cases including data warehousing, data lakes, data engineering, data science, data application development, and data sharing. The cloud-native architecture consists of layers across storage, compute, and cloud services. The storage layer ingests structured and semi-structured data to create a unified data record. The compute layer provides dedicated resources to enable users to access common data sets for many use cases without latency. The cloud services layer optimizes each use case's performance requirements with no administration. The company was founded by Marcin Zukowski, Thierry Cruanes, and Benoit Dageville on July 23, 2012 and is headquartered in Menlo Park, CA.

Snowflake Inc

Snowflake shares surged significantly following a quarterly report that featured a beat on both top and bottom-line estimates and an upward revision to full-year product revenue guidance. While retail sentiment is overwhelmingly bullish due to accelerating AI-driven demand and consumption growth, some traders remain skeptical, pointing to the company's non-GAAP accounting, lack of GAAP profitability, and premium valuation.

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc

Ultragenyx shares have plummeted following the failure of its late-stage Aspire trial for the Angelman syndrome therapy GTX-102, which missed both its primary and secondary endpoints. While the news triggered widespread analyst downgrades and significant share price declines, some members of the community are viewing the sell-off as an overreaction, pointing to the company's existing commercial revenue and upcoming regulatory catalysts as potential sources of recovery.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending as traders speculate on a potential short squeeze and re-rating ahead of upcoming earnings, fueled by recent analyst price target hikes and bullish sentiment surrounding the company's shift toward agentic AI. The conversation remains polarized, with some investors betting on explosive upside while others express skepticism regarding future revenue growth and executive leadership.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The SPY is trending as traders react to Federal Reserve Governor Christopher Waller’s dovish comments, which lowered the probability of a September rate hike and sparked a broad market rally. While some investors are expressing caution over geopolitical tensions and persistent inflation, bullish sentiment remains strong as many traders continue to favor call options despite high volatility.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus

Xenon posts a narrower-than-expected Q2 loss as azetukalner advances toward a planned FDA filing, while its cash runway is expected to support operations into 2029.

Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why

XENE's shares climb 22% in six months as azetukalner delivers strong phase III epilepsy data and advances across multiple late-stage studies.

What to Know About This Fund's New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing

What to Know About This Fund's New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing...

Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus

XENE's Q1 loss matches estimates, while phase III azetukalner data, cash growth and late-stage pipeline progress stay in focus.

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +17.95% and -33.14%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from Brokerages

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) have been given a consensus recommendation of "Buy" by the eighteen analysts that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, fifteen have given a bu...

Xenon Pharmaceuticals (XENE) Projected to Post Quarterly Earnings on Monday

Xenon Pharmaceuticals (NASDAQ:XENE) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at...

Jennison Associates LLC Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE

Jennison Associates LLC boosted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 13.8% during the fourth quarter, according to the company in its most recent...

Pictet Asset Management Holding SA Cuts Position in Xenon Pharmaceuticals Inc. $XENE

Pictet Asset Management Holding SA decreased its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 50.4% in the fourth quarter, according to its most recent Form 13F...

Reported GAAP EPS of -$1.11 down -3.74% YoY

Xenon Pharmaceuticals Inc. faces significant risks including recurring operating losses, substantial dependence on the successful development of azetukalner, and reliance on third-party contractors for critical clinical and pre-clinical study execution.

Xenon Pharmaceuticals Inc. is advancing its late-stage azetukalner pipeline toward a 2026 NDA submission while maintaining a robust cash position of $1,245.1 million to support ongoing clinical development and operations.

Xenon Pharmaceuticals, Inc. is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc

XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’

Equity

Neutral Sentiment

The Federal Reserve hasn't raised rates at all in 2026, but hawkish comments from Fed Chair Kevin Warsh at the Jackson Hole symposium have pushed September rate hike odds as high as 66%, a sharp jump from under 40% just a week earlier. How many rate hikes do you expect from the Fed in 2026? Vote and explain your reasoning in the comments.

How many rate hikes do you expect from the Fed in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$1.14	--	--	N/A
Q2 '26	-$1.14	-$1.11	2.76%	BEAT
Q1 '26	-$1.18	-$1.17	0.81%	BEAT
Q4 '25	-$1.19	-$1.31	-10.52%	MISSED
Q3 '25	-$1.15	-$1.15	0.21%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings